Document:

Exhibit 4.1

 

DEFINITIVE

SHARE EXCHANGE AGREEMENT

 

This

Definitive Share Exchange Agreement (“Agreement”), dated as of February 10, 2022, is between MySpray Therapeutics Inc. (“MySpray”),

a Saskatchewan, Canadian corporation located at Drawer 188, 36 Fourth Avenue North, Yorkton, Saskatchewan, Canada, S3N 2V7, Nichol Martinuik

(“Martinuik”) and Rachel Martinuik (“R. Martinuik”), the sole officers, directors, and shareholders of MySpray,

with addresses at 125 Railway Avenue East, Canora, Saskatchewan, Canada, S0A0L0, Adorbs Inc. (“ADOB”), located at 234 E.

Beech St. Long Beach, New York 11561, Qatar Consulting Inc. & Company (“Qatar”), Broadway Creative Consultants Corp.

(“Broadway”), a Saskatchewan, Canada corporation, and David Lazar (“Lazar”), as the sole officer and director

of ADOB and as the managing member of Activist Investing LLC (“Activist”). Collectively, Martinuik, MySpray, ADOB, R. Martinuik,

Qatar, Broadway, Lazar, and Activist are the “Parties.”

 

The

parties hereby enter into this Agreement, following which,

 

		1.	ADOB

will own 100 Class A common shares of MySpray, representing all of its issued and outstanding shares;

 

		2.	Martinuik

and R. Martinuik, pro-rata, will own 455,000,000 shares of ADOB common shares, out of the 644,889,500 to be issued and outstanding shares

of ADOB, following the Closing and the increase in authorized shares, as contemplated herein, representing 70.55% of ADOB’s outstanding

shares (the “Share Exchange”), calculated post-issuance;

 

		3.	51,110,500 shares of
                                                                                                                                                                  common stock of ADOB are to be issued to the Parties, pro-rata, at the Closing, and 569,889,500 shares of common stock of ADOB are
                                                                                                                                                                  to be issued to the Parties, pro-rata, upon the increase in authorized shares of common stock of ADOB to 700,000,000 as contemplated
                                                                                                                                                                  herein;

 

		4.	Martinuik

and R. Martinuik will relinquish their 100 Class A common shares of MySpray, to ADOB, in MySpray becoming the wholly-owned subsidiary

of ADOB;

 

		5.	ADOB

will issue the following shares of common stock, in exchange for the services provided in organizing and executing the Share Exchange

(as defined below): 69,000,000 shares to Qatar, 69,000,000 shares to Broadway, and 28,000,000 shares to Activist (in addition to the

21,000,000 currently held by Activist), and such issuance, when completed, shall be full payment for any such services and as full consideration

hereunder and under any Collateral Documents, as agreed to herein by Qatar, Broadway, Lazar, and Activist;

 

		6.	The

newly issued shares of ADOB shall be issued, pro-rata, to the Parties, as applicable, (i) at the Closing of the Share Exchange, and (ii)

upon the increase in authorized shares of ADOB, as contemplated herein;

 

		7.	ADOB

shall file to change its name to Soul Biotechnology Corporation, and its ticker symbol to “SOUL,” or substantially similar

to “SOUL.”

 

     

     

    

 

As

a result of this Agreement, ADOB will be filing a Form 8-K reflecting this change of control (sometimes called a “Super 8-K”).

The first consolidated post-acquisition report will be the Form 10-Q for the quarter ended March 31, 2022.

 

RECITALS

 

WHEREAS,

Martinuik and R. Martinuik currently hold all 100 Class A common shares, with a stated capital of $100 (all figures in Canadian dollars),

of the issued and outstanding shares of MySpray and are desirous of relinquishing all of their MySpray shares so that they would own

455,000,000 shares of ADOB common stock and that 644,889,500 shares of ADOB common stock would be outstanding; their ownership would

represent 70.55% of ADOB’s outstanding shares; and that MySpray would be a wholly-owned subsidiary of ADOB.

 

WHEREAS,

MySpray is desirous of becoming a wholly-owned subsidiary of ADOB, a fully reporting public company.

 

WHEREAS,

ADOB and MySpray are desirous of ADOB acquiring 100% of the outstanding shares of MySpray, issuing 621,000,000 shares of ADOB common

stock to the Parties, as applicable, in the process, making MySpray a wholly-owned subsidiary of ADOB.

 

WHEREAS,

The Parties are desirous of ADOB issuing the following shares of common stock, in exchange for the services provided in organizing

and executing the Share Exchange: 69,000,000 shares to Qatar, 69,000,000 shares to Broadway, and 28,000,000 shares to Activist.

 

WHEREAS,

The Parties are desirous of ADOB (i) increasing the authorized shares of ADOB common stock to 700,000,000, (ii) changing the name

of ADOB to “Soul Biotechnology Corporation”, (iii) requesting a ticker symbol change to “SOUL,” or substantially

similar.

 

WHEREAS,

the board of directors and shareholders of ADOB and MySpray, respectively, have each agreed to exchange and issue shares, as necessary

to cause the forgoing results (the “Share Exchange”), upon the terms, and subject to the conditions, set forth in this Agreement,

including the board of directors and shareholders of ADOB (i) increasing the authorized shares of ADOB common stock to 700,000,000, (ii)

changing the name of ADOB to “Soul Biotechnology Corporation”, (iii) requesting a ticker symbol change to “SOUL,”

or substantially similar.

 

WHEREAS,

it is intended that, for federal income tax purposes, the Share Exchange shall qualify as a reorganization under the provisions of Section

368(a)(1)(B) of the Internal Revenue Code of 1986, as amended (the “Code”), and the rules and regulations promulgated thereunder,

and be tax-free pursuant to Section 351(a) of the Code.

 

AND

WHEREAS, the Parties desire to make certain representations, warranties, covenants and agreements in connection with this Agreement.

 

NOW,

THEREFORE, in consideration of the premises and mutual promises herein made, and in consideration of the representations, warranties,

covenants and agreements herein contained, and intending to be legally bound hereby, the Parties agree as follows:

 

INCORPORATION

OF RECITALS BY REFERENCE. The Recitals are hereby incorporated herein by this reference, as if fully restated herein.

 

    2

     

    

 

ARTICLE

I

DEFINITIONS

 

I.1 Certain

Definitions. The following terms shall, when used in this Agreement, have the following meanings:

 

“Acquisition”

means the acquisition of any businesses, assets or property other than in the ordinary course, whether by way of the purchase of assets

or stock, by ADOB acquiring all of the outstanding shares of MySpray pursuant to this Share Exchange Agreement and ADOB issuing shares

of common stock to the Parties, as contemplated herein.

 

“ADOB

Business” means the business conducted by ADOB.

 

“ADOB

Common Stock” means the common shares of ADOB.

 

“ADOB

Securities Filings” means ADOB’s Annual Report on Form 10-K and its quarterly reports on Form 10-Q, and all other reports

filed and to be filed with the Commission prior to the Effective Time.

 

“Affiliate”

means, with respect to any Person: (i) any Person directly or indirectly owning, controlling or holding with power to vote ten percent

(10%) or more of the outstanding voting securities of such other Person (other than passive or institutional investors); (ii) any Person

ten percent (10%) or more of whose outstanding voting securities are directly or indirectly owned, controlled or held with power to vote,

by such other Person; (iii) any Person directly or indirectly controlling, controlled by or under common control with such other Person;

and (iv) any officer, director or partner of such other Person. “Control” for the foregoing purposes shall mean the possession,

directly or indirectly, of the power to direct or cause the direction of the management and policies of a Person, whether through the

ownership of voting securities or voting interests, by contract or otherwise.

 

“Business

Day” means any day other than Saturday, Sunday or a day on which banking institutions in Los Angeles, California, are required

or authorized to be closed.

 

“Code”

means the United States Internal Revenue Code of 1986, as amended.

 

“Collateral

Documents” mean the Exhibits and any other documents, instruments and certificates to be executed and delivered by the Parties

hereunder or there under.

 

“Commission”

means the Securities and Exchange Commission or any Regulatory Authority that succeeds to its functions.

 

“Effective

Time” means, the moment in time when the shares of the MySpray are exchanged for the shares of ADOB.

 

    3

     

    

 

“Encumbrance”

means any material mortgage, pledge, lien, encumbrance, charge, security interest, security agreement, conditional sale or other title

retention agreement, limitation, option, assessment, restrictive agreement, restriction, adverse interest, restriction on transfer or

exception to or material defect in title or other ownership interest (including restrictive covenants, leases and licenses).

 

“Exchange

Act” means the Securities Exchange Act of 1934, as amended, and the rules and regulations there under.

 

“Exchange

Shares” means the 100 Class A issued and outstanding common shares of MySpray (the “MySpray Shares”), exchanged by

Martinuik and R. Martinuik to ADOB, for 621,000,000 newly issued shares of ADOB (the “ADOB Shares”), to be issued to the

Parties, as applicable.

 

“GAAP”

means United States generally accepted accounting principles as in effect from time to time.

 

“Legal

Requirement” means any statute, ordinance, law, rule, regulation, code, injunction, judgment, order, decree, ruling, or other requirement

enacted, adopted or applied by any Regulatory Authority, including judicial decisions applying common law or interpreting any other Legal

Requirement.

 

“Losses”

shall mean all damages, awards, judgments, assessments, fines, sanctions, penalties, charges, costs, expenses, payments, diminutions

in value and other losses, however suffered or characterized, all interest thereon, all costs and expenses of investigating any claim,

lawsuit or arbitration and any appeal there from, all actual attorneys’, accountants’ investment bankers’ and expert

witness’ fees incurred in connection therewith, whether or not such claim, lawsuit or arbitration is ultimately defeated and, subject

to Section 9.4, all amounts paid incident to any compromise or settlement of any such claim, lawsuit or arbitration.

 

“Liability”

means any liability or obligation (whether known or unknown, whether asserted or unasserted, whether absolute or contingent, whether

accrued or unaccrued, whether liquidated or unliquidated, and whether due or to become due), including any liability for Taxes.

 

“Material

Adverse Effect” means a material adverse effect on (i) the assets, Liabilities, properties or business of the Parties, (ii) the

validity, binding effect or enforceability of this Agreement or the Collateral Documents or (iii) the ability of any Party to perform

its obligations under this Agreement and the Collateral Documents; provided, however, that none of the following shall constitute a Material

Adverse Effect on ADOB: (i) the filing, initiation and subsequent prosecution, by or on behalf of shareholders of any Party, of litigation

that challenges or otherwise seeks damages with respect to the Share Exchange, this Agreement and/or transactions contemplated thereby

or hereby, (ii) occurrences due to a disruption of a Party’s business as a result of the announcement of the execution of this

Agreement or changes caused by the taking of action required by this Agreement, (iii) general economic conditions, or (iv) any changes

generally affecting the industries in which a Party operates.

 

“Permit”

means any license, permit, consent, approval, registration, authorization, qualification or similar right granted by a Regulatory Authority.

 

    4

     

    

 

“Permitted

Liens” means (i) liens for Taxes not yet due and payable or being contested in good faith by appropriate proceedings; (ii) rights

reserved to any Regulatory Authority to regulate the affected property; (iii) statutory liens of banks and rights of set off; (iv) as

to leased assets, interests of the lessors and sub-lessors thereof and liens affecting the interests of the lessors and sub-lessors thereof;

(v) inchoate material men’s, mechanics’, workmen’s, repairmen’s or other like liens arising in the ordinary course

of business; (vi) liens incurred or deposits made in the ordinary course in connection with workers’ compensation and other types

of social security; (vii) licenses of trademarks or other intellectual property rights granted by ADOB, in the ordinary course and not

interfering in any material respect with the ordinary course of the business of ADOB; and (viii) as to real property, any encumbrance,

adverse interest, constructive or other trust, claim, attachment, exception to or defect in title or other ownership interest (including,

but not limited to, reservations, rights of entry, rights of first refusal, possibilities of reversion, encroachments, easement, rights

of way, restrictive covenants, leases, and licenses) of any kind, which otherwise constitutes an interest in or claim against property,

whether arising pursuant to any Legal Requirement, under any contract or otherwise, that do not, individually or in the aggregate, materially

and adversely affect or impair the value or use thereof as it is currently being used in the ordinary course.

 

“Person”

means any natural person, corporation, partnership, trust, unincorporated organization, association, Limited Liability Company, Regulatory

Authority or other entity.

 

“Proposed

Acquisition” means any of the following transactions (other than the transactions contemplated by this Agreement): (i) a merger,

consolidation, business combination, recapitalization, liquidation, dissolution or similar transaction involving ADOB pursuant to which

the shareholders of ADOB immediately preceding such transaction hold less than fifty percent (50%) of the aggregate equity interests

in the surviving or resulting entity of such transaction, (ii) a sale or other disposition by ADOB of assets representing in excess of

fifty percent (50%) of the aggregate fair market value of ADOB Business immediately prior to such sale or (iii) the acquisition by any

person or group (including by way of a tender offer or an exchange offer or issuance by ADOB), directly or indirectly, of beneficial

ownership or a right to acquire beneficial ownership of shares representing in excess of fifty percent (50%) of the voting power of the

then outstanding shares of capital stock of ADOB.

 

“Regulatory

Authority” means: (i) the United States of America; (ii) any state, commonwealth, territory or possession of the United States

of America and any political subdivision thereof (including counties, municipalities and the like); (iii) Canada and any other foreign

(as to the United States of America) sovereign entity and any political subdivision thereof; or (iv) any agency, authority or instrumentality

of any of the foregoing, including any court, tribunal, department, bureau, commission or board.

 

“Representative”

means any director, officer, employee, agent, consultant, advisor or other representative of a Person, including legal counsel, accountants

and financial advisors.

 

“Securities

Act” means the Securities Act of 1933, as amended, and the rules and regulations there under.

 

“Subsidiary”

of a specified Person means (a) any Person if securities having ordinary voting power (at the time in question and without regard to

the happening of any contingency) to elect a majority of the directors, trustees, managers or other governing body of such Person are

held or controlled by the specified Person or a Subsidiary of the specified Person; (b) any Person in which the specified Person and

its subsidiaries collectively hold a fifty percent (50%) or greater equity interest; (c) any partnership or similar organization in which

the specified Person or subsidiary of the specified Person is a general partner; or (d) any Person the management of which is directly

or indirectly controlled by the specified Person and its Subsidiaries through the exercise of voting power, by contract or otherwise.

 

    5

     

    

 

“Tax”

means any U.S. or non U.S. federal, state, provincial, local or foreign income, gross receipts, license, payroll, employment, excise,

severance, stamp, occupation, premium, windfall profits, environmental, customs duties, capital, franchise, profits, withholding, social

security (or similar), unemployment, disability, real property, personal property, intangible property, recording, occupancy, sales,

use, transfer, registration, value added minimum, estimated or other tax of any kind whatsoever, including any interest, additions to

tax, penalties, fees, deficiencies, assessments, additions or other charges of any nature with respect thereto, whether disputed or not.

 

“Tax

Return” means any return, declaration, report, claim for refund or credit or information return or statement relating to Taxes,

including any schedule or attachment thereto, and including any amendment thereof.

 

“Treasury

Regulations” means regulations promulgated by the U.S. Treasury Department under the Code.

 

ARTICLE

II

THE SHARE EXCHANGE

 

II.1 Share

Exchange. In accordance with and subject to the provisions of this Agreement and the Nevada Corporations, Partnerships and

Associations Law Annotated (the “Code”), at the Effective Time, MySpray shall become a wholly-owned subsidiary of ADOB,

and ADOB shall be its only shareholder and shall continue in its existence with one owner, ADOB, until a merger, if any. Pursuant to

the Share Exchange, (i) Martinuik and R. Martinuik are relinquishing all of their 100 Class A MySpray common shares, constituting

all issued and outstanding shares of MySpray (the “MySpray Shares”), and are acquiring 455,000,000 shares of ADOB,

representing 70.55% of the outstanding shares of ADOB, and (ii) ADOB is issuing an additional 166,000,000 shares of its common stock

to Qatar, Broadway and Activist, as applicable (together with the issuance to Martinuik and R. Martinuik, the “ADOB

Shares”); ADOB is issuing 621,000,000 of its shares, and is acquiring the 100 MySpray Shares; and MySpray is becoming the

wholly-owned subsidiary of ADOB.

 

II.2 Stock

Transfer Books. Effective immediately, the stock transfer books of ADOB shall be closed, and there shall be no further issuance

or registration of transfers of shares hereafter on the records of ADOB, until after the completion of the Share

Exchange.

 

II.3 Restriction

on Transfer. The Exchange Shares may not be sold, transferred, or otherwise disposed of without registration under the Act or an

exemption therefrom, and that in the absence of an effective registration statement covering the Share Exchange Shares or any available

exemption from registration under the Act, the Share Exchange Shares must be held indefinitely. The Parties are aware that the Share

Exchange Shares may not be sold pursuant to Rule 144 promulgated under the Act unless all of the conditions of that Rule are met. Among

the conditions for use of Rule 144 may be the availability of current information to the public about the Surviving Company.

 

II.4 Restrictive

Legend. All certificates representing the Exchange Shares shall contain an appropriate restrictive legend.

 

II.5 Closing.

The closing of the transactions contemplated by this Agreement and the Collateral Documents (the “Closing”) shall take place

via conference call at the offices of McMurdo Law Group, LLC, 1185 Avenue of the Americas, 3rd Floor, New York, NY 10036,

or at such other location as the parties may agree at 10:00 AM, EST Time on the agreed date, which, shall be concurrent with the signing

hereof (the “Closing Date”).

 

    6

     

    

 

ARTICLE

III

REPRESENTATIONS AND WARRANTIES OF ADOB

 

ADOB

represents and warrants to Martinuik and R. Martinuik that the statements contained in this ARTICLE III are correct and complete as of

the date of this Agreement and, except as provided in Section 7.1, will be correct and complete as of the Closing Date (as though made

then and as though the Closing Date were substituted for the date of this Agreement throughout this ARTICLE III, except in the case of

representations and warranties stated to be made as of the date of this Agreement or as of another date and except for changes contemplated

or permitted by this Agreement).

 

III.1

Organization and Qualification. ADOB is a corporation duly organized, validly existing and in good standing under the laws of

its respective jurisdiction of organization. ADOB has all requisite power and authority to own, lease and use its assets as they are

currently owned, leased and used and to conduct its business as it is currently conducted. ADOB is duly qualified or licensed to do business

in and is in good standing in each jurisdiction in which the character of the properties owned, leased or used by it or the nature of

the activities conducted by it make such qualification necessary, except any such jurisdiction where the failure to be so qualified or

licensed would not have a Material Adverse Effect on ADOB or a material adverse effect on the validity, binding effect or enforceability

of this Agreement or the Collateral Documents or the ability of ADOB to perform its obligations under this Agreement or any of the Collateral

Documents.

 

III.2

Capitalization.

 

(a)

The authorized capital stock and other ownership interests of ADOB, a Nevada corporation, consists of 75,000,000 common shares of Common

Stock, of which 23,889,500 were issued and outstanding as of December 31, 2021. ADOB has no shares of Preferred Stock authorized. All

of the outstanding ADOB Common have been duly authorized and are validly issued, fully paid and non-assessable.

 

(b)

Other than what has been described herein or in ADOB’s SEC Documents, there are no outstanding or authorized options, warrants,

purchase rights, preemptive rights or other contracts or commitments that could require ADOB to issue, sell, or otherwise cause to become

outstanding any of its capital stock or other ownership interests (collectively “Options”).

 

(c)

All of the issued and outstanding shares of ADOB Common Stock have been duly authorized and are validly issued and outstanding, fully

paid and non-assessable and have been issued in compliance with applicable securities laws and other applicable Legal Requirements or

transfer restrictions under applicable securities laws.

 

III.3

Authority and Validity. ADOB has all requisite corporate power to execute and deliver, to perform its obligations under, and to

consummate the transactions contemplated by, this Agreement (subject to the approval of ADOB Shareholders as contemplated herein and

subject to the receipt of any necessary consents, approvals, authorizations or other matters referred to herein). The execution and delivery

by ADOB of, the performance by ADOB of its obligations under, and the consummation by ADOB of the transactions contemplated by, this

Agreement have been duly authorized by all requisite action of ADOB (subject to the approval of ADOB Shareholders as contemplated herein).

This Agreement has been duly executed and delivered by ADOB and (assuming due execution and delivery by Martinuik and R. Martinuik and

approval by ADOB Shareholders) is the legal, valid and binding obligation of ADOB, enforceable against it in accordance with its terms,

except that such enforcement may be subject to (i) bankruptcy, insolvency, reorganization, moratorium or other similar laws affecting

or relating to enforcement of creditors’ rights generally and (ii) general equitable principles. Upon the execution and delivery

of the Collateral Documents by each Person (other than by Martinuik and R. Martinuik) that is required by this Agreement to execute,

or that does execute, this Agreement or any of the Collateral Documents, and assuming due execution and delivery thereof by Martinuik

and R. Martinuik, the Collateral Documents will be the legal, valid and binding obligations of ADOB, enforceable against ADOB in accordance

with their respective terms, except that such enforcement may be subject to (i) bankruptcy, insolvency, reorganization, moratorium or

other similar laws affecting or relating to enforcement of creditors’ rights generally and (ii) general equitable principles.

 

    7

     

    

 

III.4

No Breach or Violation. Subject to obtaining the consents, approvals, authorizations, and orders of and making the registrations

or filings with or giving notices to Regulatory Authorities and Persons identified herein, the execution, delivery and performance by

ADOB of this Agreement and the Collateral Documents to which it is a party, and the consummation of the transactions contemplated hereby

and thereby in accordance with the terms and conditions hereof and thereof, do not and will not conflict with, constitute a violation

or breach of, constitute a default or give rise to any right of termination or acceleration of any right or obligation of ADOB under,

or result in the creation or imposition of any Encumbrance upon ADOB, ADOB Assets, ADOB Business or ADOB Common Stock by reason of the

terms of (i) the articles of incorporation, by laws or other charter or organizational document of ADOB or any Subsidiary of ADOB, (ii)

any material contract, agreement, lease, indenture or other instrument to which ADOB is a party or by or to which ADOB, or the Assets

may be bound or subject and a violation of which would result in a Material Adverse Effect on ADOB, (iii) any order, judgment, injunction,

award or decree of any arbitrator or Regulatory Authority or any statute, law, rule or regulation applicable to ADOB or (iv) any Permit

of ADOB, which in the case of (ii), (iii) or (iv) above would have a Material Adverse Effect on ADOB or a material adverse effect on

the validity, binding effect or enforceability of this Agreement or the Collateral Documents or the ability of ADOB to perform its obligations

under this Agreement or any of the Collateral Documents.

 

III.5

Consents and Approvals. Except for requirements described in Schedule 3.5, no consent, approval, authorization or order of, registration

or filing with, or notice to, any Regulatory Authority or any other Person is necessary to be obtained, made or given by ADOB in connection

with the execution, delivery and performance by ADOB of this Agreement or any Collateral Document or for the consummation by ADOB of

the transactions contemplated hereby or thereby, except to the extent the failure to obtain any such consent, approval, authorization

or order or to make any such registration or filing would not have a Material Adverse Effect on ADOB or a material adverse effect on

the validity, binding effect or enforceability of this Agreement or the Collateral Documents or the ability of ADOB to perform its obligations

under this Agreement or any of the Collateral Documents.

 

III.6

Intellectual Property. ADOB warrants that it has good title to or the right to use all material company intellectual property

rights and all material inventions, processes, designs, formulae, trade secrets and know how necessary for the operation of ADOB Business

without the payment of any royalty or similar payment.

 

III.7

Compliance with Legal Requirements. ADOB has operated its business in compliance with all Legal Requirements applicable to ADOB

except to the extent the failure to operate in compliance with all material Legal Requirements would not have a Material Adverse Effect

on ADOB or Material Adverse Effect on the validity, binding effect or enforceability of this Agreement or the Collateral Documents.

 

    8

     

    

 

III.8

Litigation. There are no outstanding judgments or orders against or otherwise affecting or related to ADOB, ADOB Business or ADOB

Assets and there is no action, suit, complaint, proceeding or investigation, judicial, administrative or otherwise, that is pending or,

to ADOB’s knowledge, threatened that, if adversely determined, would have a Material Adverse Effect on ADOB or a material adverse

effect on the validity, binding effect or enforceability of this Agreement or the Collateral Documents, except as noted in the audited

Company Financial Statements or documented by ADOB to Martinuik and R. Martinuik.

 

III.9

Taxes. ADOB has duly and timely filed in proper form all Tax Returns for all Taxes required to be filed with the appropriate Regulatory

Authority, and has paid all taxes required to be paid in respect thereof except where such failure would not have a Material Adverse

Effect on ADOB, except where, if not filed or paid, the exception(s) have been documented by ADOB to Martinuik and R. Martinuik.

 

III.10

Books and Records. The books and records of ADOB accurately and fairly represent ADOB Business and its results of operations in

all material respects.

 

III.11

Brokers or Finders. All negotiations relative to this Agreement and the transactions contemplated hereby have been carried out

by ADOB and/or its Affiliates/Representatives in connection with the transactions contemplated by this Agreement, neither ADOB, nor any

of its Affiliates/Representatives have incurred any obligation to pay any brokerage or finder’s fee or other commission in connection

with the transaction contemplated by this Agreement.

 

III.12

Disclosure. No representation or warranty of ADOB in this Agreement or in the Collateral Documents and no statement in any certificate

furnished or to be furnished by ADOB pursuant to this Agreement contained, contains or will contain on the date such agreement or certificate

was or is delivered, or on the Closing Date, any untrue statement of a material fact, or omitted, omits or will omit on such date to

state any material fact necessary in order to make the statements made, in light of the circumstances under which they were made, not

misleading.

 

III.13

No Undisclosed Liabilities. ADOB is not subject to any material liability (including unasserted claims), absolute or contingent,

which is not shown or which is in excess of amounts shown or reserved for in the balance sheet as of September 30, 2021 other than liabilities

of the same nature as those set forth in ADOB Financial Statements and reasonably incurred in the ordinary course of its business after

September 30, 2021.

 

    9

     

    

 

III.14

Absence of Certain Changes.Since September 30, 2021, ADOB has not: (a) suffered any material adverse change in its financial

condition, assets, liabilities or business; (b) contracted for or paid any capital expenditures; (c) incurred any indebtedness or borrowed

money, issued or sold any debt or equity securities, declared any dividends or discharged or incurred any liabilities or obligations

except in the ordinary course of business as heretofore conducted; (d) mortgaged, pledged or subjected to any lien, lease, security interest

or other charge or encumbrance any of its properties or assets; (e) paid any material amount on any indebtedness prior to the due date,

forgiven or cancelled any material amount on any indebtedness prior to the due date, forgiven or cancelled any material debts or claims

or released or waived any material rights or claims; (f) suffered any damage or destruction to or loss of any assets (whether or not

covered by insurance); (g) acquired or disposed of any assets or incurred any liabilities or obligations; (h) made any payments to its

affiliates or associates or loaned any money to any person or entity; (i) formed or acquired or disposed of any interest in any corporation,

partnership, limited liability company, joint venture or other entity; (j) entered into any employment, compensation, consulting or collective

bargaining agreement or any other agreement of any kind or nature with any person. Or group, or modified or amended in any respect the

terms of any such existing agreement; (k) entered into any other commitment or transaction or experience any other event that relates

to or affect in any way this Agreement or to the transactions contemplated hereby, or that has affected, or may adversely affect ADOB

Business, operations, assets, liabilities or financial condition; or (1) amended its Articles of Incorporation or By-laws, except as

otherwise contemplated herein.

 

III.15

Contracts. A true and complete list of all contracts, agreements, leases, commitments or other understandings or arrangements,

written or oral, express or implied, to which ADOB is a party or by which it or any of its property is bound or affected requiring payments

to or from, or incurring of liabilities by, ADOB in excess of $100,000 (the “Contracts”). The Company has complied with and

performed, in all material respects, all of its obligations required to be performed under and is not in default with respect to any

of the Contracts, as of the date hereof, nor has any event occurred which has not been cured which, with or without the giving of notice,

lapse of time, or both, would constitute a default in any respect there under. To the best knowledge of ADOB, no other party has failed

to comply with or perform, in all material respects, any of its obligations required to be performed under or is in material default

with respect to any such Contracts, as of the date hereof, nor has any event occurred which, with or without the giving of notice, lapse

of time or both, would constitute a material default in any respect by such party there under. ADOB knows of and has no reason to believe

that there are any facts or circumstances which would make a material default by any party to any contract or obligation likely to occur

subsequent to the date hereof.

 

III.16

Permits and Licenses. ADOB has all certificates of occupancy, rights, permits, certificates, licenses, franchises, approvals and

other authorizations as are reasonably necessary to conduct its business and to own, lease, use, operate and occupy its assets, at the

places and in the manner now conducted and operated, except those the absence of which would not materially adversely affect its business.

ADOB has not received any written or oral notice or claim pertaining to the failure to obtain any material permit, certificate, license,

approval or other authorization required by any federal, state or local agency or other regulatory body, the failure of which to obtain

would materially and adversely affect its business.

 

III.17

Assets Necessary to Business. ADOB owns or leases all properties and assets, real, personal, and mixed, tangible and intangible,

and is a party to all licenses, permits and other agreements necessary to permit it to carry on its business as presently conducted.

 

III.18

Labor Agreements and Labor Relations. ADOB has no collective bargaining or union contracts or agreements. ADOB is in compliance

with all applicable laws respecting employment and employment practices, terms and conditions of employment and wages and hours, and

is not engaged in any unfair labor practices; there are no charges of discrimination or unfair labor practice charges” or complaints

against ADOB pending or threatened before any governmental or regulatory agency or authority; and, there is no labor strike, dispute,

slowdown or stoppage actually pending or threatened against or affecting ADOB.

 

    10

     

    

 

III.19

Employment Arrangements. ADOB has no employment or consulting agreements or arrangements, written or oral, which are not terminable

at the will of ADOB, or any pension, profit-sharing, option, other incentive plan, or any other type of employment benefit plan as defined

in ERISA or otherwise, or any obligation to or customary arrangement with employees for bonuses, incentive compensation, vacations, severance

pay, insurance or other benefits. No employee of ADOB is in violation of any employment agreement or restrictive covenant.

 

ARTICLE

IV

REPRESENTATIONS AND WARRANTIES OF MARTINUIK AND R. MARTINUIK

 

Martinuik

and R. Martinuik represent and warrant to ADOB that the statements contained in this ARTICLE IV are correct and complete as of the date

of this Agreement and, except as provided in Section 8.1, will be correct and complete as of the Closing Date (as though made then and

as though the Closing Date were substituted for the date of this Agreement throughout this ARTICLE IV, except in the case of representations

and warranties stated to be made as of the date of this Agreement or as of another date and except for changes contemplated or permitted

by the Agreement).

 

IV.1

Organization and Qualification. MySpray have all requisite power and authority to own, lease and use MySpray’s assets as

they are currently owned, leased and used and to conduct its business as it is currently conducted. MySpray is duly qualified or licensed

to do business in and are each in good standing in each jurisdiction in which the character of the properties owned, leased or used by

it or the nature of the activities conducted by it makes such qualification necessary, except any such jurisdiction where the failure

to be so qualified or licensed and in good standing would not have a Material Adverse Effect on MySpray or a Material Adverse Effect

on the validity, binding effect or enforceability of this Agreement or the Collateral Documents or the ability of ADOB or Martinuik and

R. Martinuik to perform their or its obligations under this Agreement or any of the Collateral Documents.

 

IV.2

Capitalization.

 

(a)

The authorized capital stock of MySpray is unlimited. All outstanding shares of MySpray Class A Common Stock are owned by Martinuik and

R. Martinuik, MySpray’s officers and directors, consisting of 100 shares. MySpray has no shares of Preferred Stock outstanding.

All 100 Shares of Class A Common Stock are duly issued and outstanding, and have been duly authorized, validly issued and outstanding

and fully paid and non-assessable, which shares are exchanged hereby, as above provided.

 

(b)

There are no outstanding or authorized options, warrants, purchase rights, preemptive rights or other contracts or commitments that could

require MySpray to issue, sell, or otherwise cause to become outstanding any of its capital stock or other ownership interests.

 

(c)

All of the issued and outstanding shares of the MySpray Capital Stock have been duly authorized and are validly issued and outstanding,

fully paid and non-assessable and have been issued in compliance with applicable securities laws and other applicable Legal Requirements.

 

    11

     

    

 

IV.3

Authority and Validity. Martinuik and R. Martinuik have all requisite power to execute and deliver to perform their obligations

under, and to consummate the transactions contemplated by, this Agreement and the Collateral Documents. The execution and delivery by

Martinuik and R. Martinuik and the performance by Martinuik and R. Martinuik of their obligations under, and the consummation by Martinuik

and R. Martinuik of the transactions contemplated by, this Agreement and the Collateral Documents have been duly authorized by all requisite

action of Martinuik and R. Martinuik. This Agreement has been duly executed and delivered (assuming due execution and delivery by Martinuik

and R. Martinuik) is the legal, valid and binding obligation of Martinuik and R. Martinuik, enforceable in accordance with its terms

except that such enforcement may be subject to (i) bankruptcy, insolvency, reorganization, moratorium or other similar laws affecting

or relating to enforcement of creditors’ rights generally and (ii) general equitable principles. Upon the execution and delivery

by Martinuik and R. Martinuik of the Collateral Documents to which he is a party, and assuming due execution and delivery thereof by

the other parties thereto, the Collateral Documents will be the legal, valid and binding obligations, enforceable in accordance with

their respective terms except that such enforcement may be subject to (i) bankruptcy, insolvency, reorganization, moratorium or other

similar laws affecting or relating to enforcement of creditors’ rights generally and (ii) general equitable principles.

 

IV.4

No Breach or Violation. Subject to obtaining the consents, approvals, authorizations, and orders of and making the registrations

or filings with or giving notices to Regulatory Authorities and Persons identified herein, the execution, delivery and performance by

Martinuik and R. Martinuik of this Agreement and the Collateral Documents to which they are parties and the consummation of the transactions

contemplated hereby and thereby in accordance with the terms and conditions hereof and thereof, do not and will not conflict with, constitute

a violation or breach of, constitute a default or give rise to any right of termination or acceleration of any right or obligation of

Martinuik and/or R. Martinuik under, or result in the creation or imposition of any Encumbrance upon the property of Martinuik and/or

R. Martinuik by reason of the terms of (i) the articles of incorporation, by laws or other charter or organizational document of MySpray, (ii) any contract, agreement, lease, indenture or other instrument to which any of Martinuik, R. Martinuik or MySpray is a party or

by or to which Martinuik, R. Martinuik or MySpray or its property may be bound or subject and a violation of which would result in a

Material Adverse Effect on Martinuik, R. Martinuik and/or MySpray taken as a whole, (iii) any order, judgment, injunction, award or decree

of any arbitrator or Regulatory Authority or any statute, law, rule or regulation applicable to Martinuik and R. Martinuik or MySpray

or (iv) any Permit of MySpray, which in the case of (ii), (iii) or (iv) above would have a Material Adverse Effect on MySpray or a material

adverse effect on the validity, binding effect or enforceability of this Agreement or the Collateral Documents or the ability of Martinuik,

or R. Martinuik or MySpray to perform their obligations hereunder or there under.

 

IV.5

Consents and Approvals. Except for requirements under applicable United States or state securities laws, no consent, approval,

authorization or order of, registration or filing with, or notice to, any Regulatory Authority or any other Person is necessary to be

obtained, made or given by Martinuik or R. Martinuik in connection with the execution, delivery and performance by them of this Agreement

or any Collateral Documents or for the consummation by them of the transactions contemplated hereby or thereby, except to the extent

the failure to obtain such consent, approval, authorization or order or to make such registration or filings or to give such notice would

not have a Material Adverse Effect on MySpray or a material adverse effect on the validity, binding effect or enforceability of this

Agreement or the Collateral Documents or the ability of Martinuik or R. Martinuik to perform their obligations under this Agreement or

any of the Collateral Documents.

 

    12

     

    

 

IV.6

Compliance with Legal Requirements. MySpray’s Business has operated in compliance with all material Legal Requirements including,

without limitation, the Exchange Act and the Securities Act applicable to MySpray, except to the extent the failure to operate in compliance

with all material Legal Requirements, would not have a Material Adverse Effect on MySpray or a Material Adverse Effect on the validity,

binding effect or enforceability of this Agreement or the Collateral Documents.

 

IV.7

Litigation. There are no outstanding judgments or orders against or otherwise affecting or related to MySpray, or the business

or assets; and there is no action, suit, complaint, proceeding or investigation, judicial, administrative or otherwise, that is pending

or, to the best knowledge of the Martinuik or R. Martinuik, threatened that, that has not been disclosed and if adversely determined,

would have a material adverse effect on the validity, binding effect or enforceability of this Agreement or the Collateral Documents.

 

IV.8

Ordinary Course. Since the date of its most recent balance sheet, there has not been any occurrence, event, incident, action,

failure to act or transaction involving MySpray, which is reasonably likely, individually or in the aggregate, to have a Material Adverse

Effect on MySpray.

 

Assets

and Liabilities. As of the date of this Agreement, MySpray has no Assets or Liability, except for the Assets and Liabilities disclosed

in the balance sheet disclosed to ADOB through the date hereof. The Liabilities of MySpray include the interest-free demand loans of

$76,109 and $93,297 as of September 30, 2021, and December 31, 2020, respectively, payable to Martinuik, in the forms attached hereto

as Exhibit A.

 

IV.9

Taxes. MySpray has duly and timely filed in proper form all Tax Returns for all Taxes required to be filed with the appropriate

Governmental Authority, except where such failure to file would not have a Material Adverse Effect on MySpray.

 

IV.10

Books and Records. The books and records of MySpray accurately and fairly represent the MySpray Business and its results of operations

in all material respects. All accounts receivable and inventory of the MySpray Business are reflected properly on such books and records

in all material respects.

 

IV.11

Financial and Other Information.

 

(a)

Two years of audited historical financial statements of MySpray, and nine months of unaudited financials, will be prepared in accordance

with GAAP applied on a consistent basis throughout the periods covered thereby (except as may be indicated in the notes thereto), and

present fairly the financial condition of MySpray and its results of operations as of the dates and for the periods indicated, subject

in the case of the unaudited financial statements only to normal year-end adjustments (none of which will be material in amount) and

the omission of footnotes.

 

(b)

To the knowledge of current management, MySpray’s financials do not contain (directly or by incorporation by reference) any untrue

statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein

(or incorporated therein by reference), in light of the circumstances under which they were or will be made, not misleading.

 

IV.12 Rental

Agreement. MySpray is a party to a verbal rental agreement with Martinuik, with the terms as provided by MySpray.

 

    13

     

    

 

IV.13

Brokers or Finders. All negotiations relative to this Agreement and the transactions contemplated hereby have been carried out

by MySpray and/or its Affiliates/Representatives in connection with the transactions contemplated by this Agreement, neither MySpray,

nor any of its Affiliates/Representatives have incurred any obligation to pay any brokerage or finder’s fee or other commission

in connection with the transaction contemplated by this Agreement.

 

IV.14

Disclosure. No representation or warranty of Martinuik or R. Martinuik in this Agreement or in the Collateral Documents and no

statement in any certificate furnished or to be furnished by Martinuik or R. Martinuik pursuant to this Agreement contained, contains

or will contain on the date such agreement or certificate was or is delivered, or on the Closing Date, any untrue statement of a material

fact, or omitted, omits or will omit on such date to state any material fact necessary in order to make the statements made, in light

of the circumstances under which they were made, not misleading.

 

IV.15

Filings. Neither MySpray nor Martinuik nor R. Martinuik is subject to filings required by the Securities Act of 1933, as amended,

and the Exchange Act of 1934, as amended. Once MySpray acquires control of ADOB, MySpray and Martinuik or R. Martinuik will make filings

required to be made under such statutes and no such filing will contain any untrue statement of a material fact or omit to state a material

fact necessary to make the statements made, not misleading.

 

IV.16

Conduct of Business. Prior to the Closing Date, MySpray shall conduct its business in the normal course, and shall not sell, pledge,

or assign any assets, without the prior written approval of ADOB, except in the regular course of business. Except as otherwise provided

herein, MySpray shall not amend its Articles of Incorporation or By-Laws, declare dividends, redeem or sell stock or other securities,

acquire or dispose of fixed assets, change employment terms, enter into any material or long-term contract, guarantee obligations of

any third party, settle or discharge any material balance sheet receivable for less than its stated amount, pay more on any liability

than its stated amount or enter into any other transaction other than in the regular course of business.

 

ARTICLE

V

COVENANTS OF ADOB

 

Between

the date of this Agreement and the Closing Date:

 

V.1

Additional Information. ADOB shall provide to Martinuik and R. Martinuik and their Representatives such financial, operating and

other documents, data and information relating to ADOB, ADOB Business and ADOB Assets and Liabilities, as Martinuik and R. Martinuik

or his Representatives may reasonably request. In addition, ADOB shall take all action necessary to enable Martinuik and R. Martinuik

and their Representatives to review, inspect and review ADOB Assets, ADOB Business and Liabilities of ADOB and discuss them with ADOB’s

officers, employees, independent accountants, customers, licensees, and counsel. Not-withstanding any investigation that Martinuik and

R. Martinuik may conduct of ADOB, ADOB Business, ADOB Assets and the Liabilities of ADOB, Martinuik and R. Martinuik may fully rely on

ADOB’s warranties, covenants and indemnities set forth in this Agreement.

 

V.2

Consents and Approvals. As soon as practicable after execution of this Agreement, ADOB shall use commercially reasonable efforts

to obtain any necessary consent, approval, authorization or order of, make any registration or filing with or give any notice to, any

Regulatory Authority or Person as is required to be obtained, made or given by ADOB to consummate the transactions contemplated by this

Agreement and the Collateral Documents.

 

    14

     

    

 

V.3

Increase in authorized shares and name change. It is understood that in completion of the transactions contemplated hereby, ADOB

is required to (i) increase its authorized share of common stock, $.001 par value per share, to 700,000,000, (ii) change the name of

ADOB to “Soul Biotechnology Corporation”, (iii) request a ticker symbol change to “SOUL,” or substantially similar.

ADOB shall file all necessary documents and reports, including an Information Statement on Form 14C, necessary in order to complete such

increase and other actions, and issue the remaining ADOB to the Parties, as applicable, pro-rata.

 

V.4

No Solicitations. From and after the date of this Agreement until the Effective Time or termination of this Agreement pursuant

to ARTICLE X, ADOB will not nor will it authorize or permit any of its officers, directors, affiliates or employees or any investment

banker, attorney or other advisor or representative retained by it, directly or indirectly, (i) solicit or initiate the making, submission

or announcement of any other acquisition proposal, (ii) participate in any discussions or negotiations regarding, or furnish to any person

any non-public information with respect to any other acquisition proposal, (iii) engage in discussions with any Person with respect to

any other acquisition proposal, except as to the existence of these provisions, (iv) approve, endorse or recommend any other acquisition

proposal or (v) enter into any letter of intent or similar document or any contract agreement or commitment contemplating or otherwise

relating to any other acquisition proposal.

 

V.5

Notification of Adverse Change. ADOB shall promptly notify Martinuik and R. Martinuik of any material adverse change in the condition

(financial or otherwise) of ADOB.

 

V.6

Notification of Certain Matters. ADOB shall promptly notify Martinuik and R. Martinuik of any fact, event, circumstance or action

known to it that is reasonably likely to cause ADOB to be unable to perform any of its covenants contained herein or any condition precedent

in ARTICLE VII not to be satisfied, or that, if known on the date of this Agreement, would have been required to be disclosed to Martinuik

and R. Martinuik pursuant to this Agreement or the existence or occurrence of which would cause any of ADOB’s representations or

warranties under this Agreement not to be correct and/or complete. ADOB shall give prompt written notice to Martinuik and R. Martinuik

of any adverse development causing a breach of any of the representations and warranties in ARTICLE III as of the date made.

 

V.7

The Company Disclosure Schedule. For purposes of determining the satisfaction of any of the conditions to the obligations of Martinuik

and R. Martinuik in ARTICLE VII, ADOB disclosures shall be deemed to include only (a) the information contained therein on the date of

this Agreement and (b) information provided by written supplements delivered prior to Closing by ADOB that (i) are accepted in writing

by Martinuik or R. Martinuik, or (ii) reflect actions taken or events occurring after the date hereof prior to Closing.

 

V.8

State Statutes. ADOB and its Board of Directors shall, if any state takeover statute or similar law is or becomes applicable to

the Share Exchange, this Agreement or any of the transactions contemplated by this Agreement, use all reasonable efforts to ensure that

the Share Exchange and the other transactions contemplated by this Agreement may be consummated as promptly as practicable on the terms

contemplated by this Agreement and otherwise to minimize the effect of such statute or regulation on the Share Exchange, this Agreement

and the transactions contemplated hereby.

 

    15

     

    

 

V.9

Conduct of Business. Prior to the Closing Date, ADOB shall conduct its business in the normal course, and shall not sell, pledge,

or assign any assets, without the prior written approval of Martinuik and R. Martinuik, except in the regular course of business. Except

as otherwise provided herein, ADOB shall not amend its Articles of Incorporation or Bylaws, declare dividends, redeem or sell stock or

other securities, acquire or dispose of fixed assets, change employment terms, enter into any material or long-term contract, guarantee

obligations of any third party, settle or discharge any material balance sheet receivable for less than its stated amount, pay more on

any liability than its stated amount, or enter into any other transaction other than in the regular course of business.

 

V.10

Securities Filings. Until closing, ADOB will timely file all reports and other documents relating to the operation of ADOB required

to be filed with the Securities and Exchange Commission, which reports and other documents do not and will not contain any misstatement

of a material fact, and do not and will not omit any material fact necessary to make the statements therein not misleading.

 

V.11

Election to ADOB’s Board of Directors. At the Effective Time of the Share Exchange, ADOB shall take all steps necessary

so that there will be at least one (1) continuing director.

 

ARTICLE

VI

COVENANTS OF MARTINUIK AND R. MARTINUIK

 

Between

the date of this Agreement and the Closing Date,

 

VI.1

Additional Information. Martinuik and R. Martinuik shall provide to ADOB and its Representatives such financial, operating and

other documents, data and information relating to MySpray, the MySpray Business and the MySpray Assets and the Liabilities of MySpray,

as ADOB or its Representatives may reasonably request. In addition, Martinuik and R. Martinuik shall take all action necessary to enable

ADOB and its Representatives to review and inspect the MySpray Assets, the MySpray Business and the Liabilities of MySpray and discuss

them with ADOB’s officers, employees, independent accountants and counsel. Notwithstanding any investigation that ADOB may conduct

of MySpray, the MySpray Business, the MySpray Assets and the Liabilities of the MySpray, ADOB may fully rely on the Martinuik’s

and R. Martinuik’s warranties, covenants and indemnities set forth in this Agreement.

 

VI.2

No Solicitations. From and after the date of this Agreement until the Effective Time or termination of this Agreement pursuant

to ARTICLE X, Martinuik and R. Martinuik will not nor will it authorize or permit any of MySpray’s officers, directors, affiliates

or employees or any investment banker, attorney or other advisor or representative retained by it, directly or indirectly, (i) solicit

or initiate the making, submission or announcement of any other acquisition proposal, (ii) participate in any discussions or negotiations

regarding, or furnish to any person any non-public information with respect to any other acquisition proposal, (iii) engage in discussions

with any Person with respect to any other acquisition proposal, except as to the existence of these provisions, (iv) approve, endorse

or recommend any other acquisition proposal or (v) enter into any letter of intent or similar document or any contract agreement or commitment

contemplating or otherwise relating to any other acquisition proposal.

 

VI.3

Notification of Adverse Change. Martinuik and R. Martinuik shall promptly notify ADOB of any material adverse change in the condition

(financial or otherwise) of MySpray.

 

    16

     

    

 

VI.4

Consents and Approvals. As soon as practicable after execution of this Agreement, Martinuik and R. Martinuik shall use his commercially

reasonable efforts to obtain any necessary consent, approval, authorization or order of, make any registration or filing with or give

notice to, any Regulatory Authority or Person as is required to be obtained, made or given by Martinuik and R. Martinuik to consummate

the transactions contemplated by this Agreement and the Collateral Documents.

 

VI.5

Notification of Certain Matters. Martinuik and R. Martinuik shall promptly notify ADOB of any fact, event, circumstance or action

known to it that is reasonably likely to cause MySpray to be unable to perform any of its covenants contained herein or any condition

precedent if not to be satisfied, or that, if known on the date of this Agreement, would have been required to be disclosed to ADOB pursuant

to this Agreement or the existence or occurrence of which would cause Martinuik’s or R. Martinuik’s representations or warranties

under this Agreement not to be correct and/or complete. Martinuik and R. Martinuik shall give prompt written notice to ADOB of any adverse

development causing a breach of any of the representations and warranties in ARTICLE IV.

 

VI.6

Audited Financial Statements. Prior to Closing, Martinuik and R. Martinuik shall provide ADOB with audited historical financial

statements of MySpray, for its last two calendar years, of prepared in accordance with GAAP applied on a consistent basis throughout

the periods covered thereby (except as may be indicated in the notes thereto), and presenting fairly the financial condition of MySpray

and its results of operations as of the dates and for the periods indicated, subject only to normal year-end adjustments (none of which

will be material in amount) and the omission of footnotes.

 

ARTICLE

VII

CONDITIONS PRECEDENT TO OBLIGATIONS OF THE PARTIES

 

All

obligations of the Parties under this Agreement shall be subject to the fulfillment at or prior to Closing of each of the following conditions,

it being understood that the Parties may, in their sole discretion, to the extent permitted by applicable Legal Requirements, waive any

or all of such conditions in whole or in part.

 

VII.1

Accuracy of Representations. All representations and warranties of ADOB contained in this Agreement, the Collateral Documents

and any certificate delivered by any of ADOB at or prior to Closing shall be, if specifically qualified by materiality, true in all respects

and, if not so qualified, shall be true in all material respects, in each case on and as of the Closing Date with the same effect as

if made on and as of the Closing Date, except for representations and warranties expressly stated to be made as of the date of this Agreement

or as of another date other than the Closing Date and except for changes contemplated or permitted by this Agreement.

 

VII.2

Covenants. ADOB shall, in all material respects, have performed and complied with each of the covenants, obligations and agreements

contained in this Agreement and the Collateral Documents that are to be performed or complied with by them at or prior to Closing.

 

VII.3

Consents and Approvals. All consents, approvals, permits, authorizations and orders required to be obtained from, and all registrations,

filings and notices required to be made with or given to, any Regulatory Authority or Person as provided herein.

 

    17

     

    

 

VII.4

Delivery of Documents. ADOB shall have delivered, or caused to be delivered, to Martinuik and R. Martinuik the following documents:

 

(i)

Copies of ADOB articles of incorporation and bylaws and certified resolutions of the board of directors of ADOB authorizing the execution

of this Agreement and the Collateral Documents to which it is a party and the consummation of the transactions contemplated hereby and

thereby.

 

(ii)

Such other documents and instruments as Martinuik and R. Martinuik may reasonably request: (A) to evidence the accuracy of ADOB’s

representations and warranties under this Agreement, the Collateral Documents and any documents, instruments or certificates required

to be delivered hereunder; (B) to evidence the performance by ADOB of, or the compliance by ADOB with, any covenant, obligation, condition

and agreement to be performed or complied with by ADOB under this Agreement and the Collateral Documents; or (C) to otherwise facilitate

the consummation or performance of any of the transactions contemplated by this Agreement and the Collateral Documents.

 

(iii)

Letters of resignation from ADOB’s current officers and directors to be effective upon the completion of the increase in authorized

shares of common stock to 700,000,000.

 

(iv)
Board resolutions from ADOB’s current directors appointing Nichol Martinuik and Rachel Martinuik as the members of ADOB’s
board of directors, effective upon the completion of the increase in authorized shares of common stock to 700,000,000.

 

VII.5

No Material Adverse Change. Since the date hereof, there shall have been no material adverse change in ADOB Assets, ADOB Business

or the financial condition or operations of ADOB, taken as a whole.

 

ARTICLE

VIII

CONDITIONS PRECEDENT TO OBLIGATIONS OF LAZAR AND ADOB

 

All

obligations of Lazar and ADOB under this Agreement shall be subject to the fulfillment at or prior to Closing of the following conditions,

it being understood that ADOB may, in its sole discretion, to the extent permitted by applicable Legal Requirements, waive any or all

of such conditions in whole or in part.

 

VIII.1

Accuracy of Representations. All representations and warranties of Martinuik and R. Martinuik contained in this Agreement and

the Collateral Documents and any other document, instrument or certificate delivered by Martinuik and R. Martinuik at or prior to the

Closing shall be, if specifically qualified by materiality, true and correct in all respects and, if not so qualified, shall be true

and correct in all material respects, in each case on and as of the Closing Date with the same effect as if made on and as of the Closing

Date, except for representations and warranties expressly stated to be made as of the date of this Agreement or as of another date other

than the Closing Date and except for changes contemplated or permitted by this Agreement.

 

VIII.2

Covenants. Martinuik and R. Martinuik shall, in all material respects, have performed and complied with each obligation, agreement,

covenant and condition contained in this Agreement and the Collateral Documents and required by this Agreement and the Collateral Documents

to be performed or complied with by Martinuik and R. Martinuik at or prior to Closing.

 

    18

     

    

 

VIII.3

Consents and Approvals. All consents, approvals, authorizations and orders required to be obtained from, and all registrations,

filings and notices required to be made with or given to, any Regulatory Authority or Person as provided herein.

 

VIII.4

Delivery of Documents. Martinuik and R. Martinuik shall have executed and delivered, or caused to be executed and delivered, to

ADOB the following documents:

 

Documents

and instruments as ADOB may reasonably request: (A) to evidence the accuracy of the representations and warranties of Martinuik and R.

Martinuik under this Agreement and the Collateral Documents and any documents, instruments or certificates required to be delivered hereunder;

(B) to evidence the performance by Martinuik and R. Martinuik of, or the compliance by Martinuik and R. Martinuik with, any covenant,

obligation, condition and agreement to be performed or complied with by Martinuik and R. Martinuik under this Agreement and the Collateral

Documents; or (C) to otherwise facilitate the consummation or performance of any of the transactions contemplated by this Agreement and

the Collateral Documents.

 

VIII.5

No Material Adverse Change. There shall have been no material adverse change in the business, financial condition or operations

of MySpray taken as a whole.

 

VIII.6

No Litigation. No action, suit or proceeding shall be pending or threatened by or before any Regulatory Authority and no Legal

Requirement shall have been enacted, promulgated or issued or deemed applicable to any of the transactions contemplated by this Agreement

and the Collateral Documents that would: (i) prevent consummation of any of the transactions contemplated by this Agreement and the Collateral

Documents; (ii) cause any of the transactions contemplated by this Agreement and the Collateral Documents to be rescinded following consummation;

or (iii) have a Material Adverse Effect on MySpray.

 

ARTICLE

IX

INDEMNIFICATION

 

IX.1

Indemnification by ADOB. ADOB shall indemnify, defend and hold harmless (i) Martinuik and R. Martinuik, (ii) any of Martinuik’s

and R. Martinuik’s assigns and successors in interest to ADOB Shares, and (iii) each of their respective shareholders, members,

partners, directors, officers, managers, employees, agents, attorneys and representatives, from and against any and all Losses which

may be incurred or suffered by any such party and which may arise out of or result from any breach of any material representation, warranty,

covenant or agreement of ADOB contained in this Agreement. All claims to be assorted hereunder must be made for the first anniversary

of the Closing.

 

IX.2

Indemnification by Martinuik and R. Martinuik. Martinuik and R. Martinuik shall, jointly and severally, indemnify, defend and

hold harmless ADOB from and against any and all Losses which may be incurred or suffered by any such party hereto and which may arise

out of or result from any breach of any material representation, warranty, covenant or agreement of Martinuik and R. Martinuik contained

in this Agreement. All claims to be assorted hereunder must be made for the first anniversary of the Closing.

 

    19

     

    

 

IX.3

Notice to Indemnifying Party. If any party (the “Indemnified Party”) receives notice of any claim or other commencement

of any action or proceeding with respect to which any other party (or parties) (the “Indemnifying Party”) is obligated to

provide indemnification pursuant to Sections 9.1 or 9.2, the Indemnified Party shall promptly give the Indemnifying Party written notice

thereof, which notice shall specify in reasonable detail, if known, the amount or an estimate of the amount of the liability arising

here from and the basis of the claim. Such notice shall be a condition precedent to any liability of the Indemnifying Party for indemnification

hereunder, but the failure of the Indemnified Party to give prompt notice of a claim shall not adversely affect the Indemnified Party’s

right to indemnification hereunder unless the defense of that claim is materially prejudiced by such failure. The Indemnified Party shall

not settle or compromise any claim by a third party for which it is entitled to indemnification hereunder without the prior written consent

of the Indemnifying Party (which shall not be unreasonably withheld or delayed) unless suit shall have been instituted against it and

the Indemnifying Party shall not have taken control of such suit after notification thereof as provided in Section 9.4.

 

IX.4

Defense by Indemnifying Party. In connection with any claim giving rise to indemnity hereunder resulting from or arising out of

any claim or legal proceeding by a Person who is not a party to this Agreement, the Indemnifying Party at its sole cost and expense may,

upon written notice to the Indemnified Party, assume the defense of any such claim or legal proceeding (i) if it acknowledges to the

Indemnified Party in writing its obligations to indemnify the Indemnified Party with respect to all elements of such claim (subject to

any limitations on such liability contained in this Agreement) and (ii) if it provides assurances, reasonably satisfactory to the Indemnified

Party, that it will be financially able to satisfy such claims in full if the same are decided adversely. If the Indemnifying Party assumes

the defense of any such claim or legal proceeding, it may use counsel of its choice to prosecute such defense, subject to the approval

of such counsel by the Indemnified Party, which approval shall not be unreasonably withheld or delayed. The Indemnified Party shall be

entitled to participate in (but not control) the defense of any such action, with its counsel and at its own expense; provided, however,

that if the Indemnified Party, in its sole discretion, determines that there exists a conflict of interest between the Indemnifying Party

(or any constituent party thereof) and the Indemnified Party, the Indemnified Party (or any constituent party thereof) shall have the

right to engage separate counsel, the reasonable costs and expenses of which shall be paid by the Indemnified Party. If the Indemnifying

Party assumes the defense of any such claim or legal proceeding, the Indemnifying Party shall take all steps necessary to pursue the

resolution thereof in a prompt and diligent manner. The Indemnifying Party shall be entitled to consent to a settlement of, or the stipulation

of any judgment arising from, any such claim or legal proceeding, with the consent of the Indemnified Party, which consent shall not

be unreasonably withheld or delayed; provided, however, that no such consent shall be required from the Indemnified Party if (i) the

Indemnifying Party pays or causes to be paid all Losses arising out of such settlement or judgment concurrently with the effectiveness

thereof (as well as all other Losses theretofore incurred by the Indemnified Party which then remain unpaid or unreimbursed), (ii) in

the case of a settlement, the settlement is conditioned upon a complete release by the claimant of the Indemnified Party and (iii) such

settlement or judgment does not require the encumbrance of any asset of the Indemnified Party or impose any restriction upon its conduct

of business.

 

    20

     

    

 

ARTICLE

X

TERMINATION

 

X.1

Termination. This Agreement may be terminated, and the transactions contemplated hereby may be abandoned, at any time prior to

it being fully executed, or thereafter:

 

(a)

by mutual written agreement of Martinuik and R. Martinuik and ADOB hereto duly authorized by action taken by or on behalf of the respective

Boards of Directors; or

 

(b)

by either ADOB or Martinuik and R. Martinuik upon notification to the non-terminating party by the terminating party:

 

(i)

if the terminating party is not in material breach of its obligations under this Agreement and there has been a material breach of any

representation, warranty, covenant or agreement on the part of the non-terminating party set forth in this Agreement such that the conditions

will not be satisfied; provided, however, that if such breach is curable by the non-terminating party and such cure is reasonably likely

to be completed prior to the date specified in Section 10.1(b)(i), then, for so long as the non-terminating party continues to use commercially

reasonable efforts to effect and cure, the terminating party may not terminate pursuant to this Section 10.1(b)(i); or

 

(ii)

if any court of competent jurisdiction or other competent Governmental or Regulatory Authority shall have issued an order making illegal

or otherwise permanently restricting, preventing or otherwise prohibiting the Share Exchange and such order shall have become final.

 

(c)

Effect of Termination. If this Agreement is validly terminated by either ADOB or Martinuik and R. Martinuik pursuant to Section

10.1, this Agreement will forthwith become null and void and there will be no liability or obligation on the part of the parties hereto,

except that nothing contained herein shall relieve any party hereto from liability for willful breach of its representations, warranties,

covenants or agreements contained in this Agreement.

 

ARTICLE

XI

MISCELLANEOUS

 

XI.1

Parties Obligated and Benefited. This Agreement shall be binding upon the Parties and their respective successors by operation

of law and shall inure solely to the benefit of the Parties and their respective successors by operation of law, and no other Person

shall be entitled to any of the benefits conferred by this Agreement. Without the prior written consent of the other Party, no Party

may assign this Agreement or the Collateral Documents or any of its rights or interests or delegate any of its duties under this Agreement

or the Collateral Documents.

 

XI.2

Publicity. The initial press release and/or Form 8-K shall be a joint press release and thereafter ADOB and Martinuik and R. Martinuik

each shall consult with each other prior to issuing any press releases or otherwise making public announcements with respect to the Share

Exchange and the other transactions contemplated by this Agreement and prior to making any filings with any third party and/or any Regulatory

Authorities (including any national securities inter dealer quotation service) with respect thereto, except as may be required by law

or by obligations pursuant to any listing agreement with or rules of any national securities inter dealer quotation service.

 

    21

     

    

 

XI.3

Notices. Any notices and other communications required or permitted hereunder shall be in writing and shall be effective upon

delivery by hand or upon receipt if sent by certified or registered mail (postage prepaid and return receipt requested) or by a nationally

recognized overnight courier service (appropriately marked for overnight delivery) or upon transmission if sent by telex or facsimile

(with request for immediate confirmation of receipt in a manner customary for communications of such respective type and with physical

delivery of the communication being made by one or the other means specified in this Section as promptly as practicable thereafter).

Notices shall be addressed as follows:

 

	 	If

to Martinuik and	 
		R.

                            Martinuik:	125

                                            RAILWAY AVENUE EAST

 CANORA, Saskatchewan, Canada, S0A0L0
	 	 	 
	 	If to ADOB:	David Lazar
	 	 	234

                                            E. Beech St.
	 	 	Long

                                            Beach, New York 11561

 

XI.4

Any Party may change the address to which notices are required to be sent by giving notice of such change in the manner provided in this

Section.

 

XI.5

Attorneys’ Fees. In the event of any action or suit based upon or arising out of any alleged breach by any Party of any

representation, warranty, covenant or agreement contained in this Agreement or the Collateral Documents, the prevailing Party shall be

entitled to recover reasonable attorneys’ fees and other costs of such action or suit from the other Party.

 

XI.6

Headings. The Article and Section headings of this Agreement are for convenience only and shall not constitute a part of this

Agreement or in any way affect the meaning or interpretation thereof.

 

XI.7

Choice of Law. This Agreement and the rights of the Parties under it shall be governed by and construed in all respects in accordance

with the laws of the State of Nevada, without giving effect to any choice of law provision or rule (whether of Saskatchewan, Canada or

any other jurisdiction).

 

XI.8

Rights Cumulative. All rights and remedies of each of the Parties under this Agreement shall be cumulative, and the exercise of

one or more rights or remedies shall not preclude the exercise of any other right or remedy available under this Agreement or applicable

law.

 

XI.9

Further Actions. The Parties shall execute and deliver to each other, from time to time at or after Closing, for no additional

consideration and at no additional cost to the requesting party, such further assignments, certificates, instruments, records, or other

documents, assurances or things as may be reasonably necessary to give full effect to this Agreement and to allow each party fully to

enjoy and exercise the rights accorded and acquired by it under this Agreement.

 

    22

     

    

 

XI.10

Time of the Essence. Time is of the essence under this Agreement. If the last day permitted for the giving of any notice or the

performance of any act required or permitted under this Agreement falls on a day which is not a Business Day, the time for the giving

of such notice or the performance of such act shall be extended to the next succeeding Business Day.

 

XI.11

Counterparts. This Agreement may be executed in one or more counterparts, each of which shall be deemed an original, but all of

which together shall constitute one and the same instrument.

 

XI.12

Entire Agreement. This Agreement (including the Exhibits, disclosures made as to ADOB, and any other documents, instruments and

certificates referred to herein, which are incorporated in and constitute a part of this Agreement) contains the entire agreement of

the Parties.

 

XI.13

Survival of Representations and Covenants. Notwithstanding any right of Martinuik and R. Martinuik to fully investigate the affairs

of ADOB and notwithstanding any knowledge of facts determined or determinable by Martinuik and R. Martinuik pursuant to such investigation

or right of investigation, Martinuik and R. Martinuik shall have the right to rely fully upon the representations, warranties, covenants

and agreements of ADOB contained in this Agreement. Each representation, warranty, covenant and agreement of ADOB contained herein shall

survive the execution and delivery of this Agreement and the Closing and shall thereafter terminate and expire on the first anniversary

of the Closing Date unless, prior to such date, Martinuik and R. Martinuik has delivered to ADOB Shareholders a written notice of a claim

with respect to such representation, warranty, covenant or agreement.

 

    23

     

    

 

IN

WITNESS WHEREOF, the Parties hereto have duly executed this Agreement as of the day and year first above written.

 

	Dated: February 10, 2022	 
	 	 
	Adorbs Inc.	 
	 	 
	By:	/s/ David Lazar	 
	Name:	David Lazar	 
	Title:	Chief Executive Officer	 
	 	 
	MySpray Therapeutics Inc. 	 
	 	 
	By:	/s/ Nichol Martinuik	 
	Name:	Nichol Martinuik	 
	Title:	President	 
	 	 
	/s/ Nichol Martinuik	 
	Nichol Martinuik	 
	 	 
	/s/ Rachel Martinuik	 
	Rachel Martinuik	 
	 	 
	Qatar Consulting Inc. & Company	 
	 	 
	By:	/s/ Ismail Abdul fattah	 
	Name:	 Ismail Abdul fattah	 
	Title:	CEO	 
	 	 
	Broadway Creative Consultants Corp.	 
	 	 
	By:	/s/ Bailey Fischl	 
	Name:	Bailey Fischl	 
	Title:	 	 
	 	 
	Activist Investing LLC	 
	 	 
	By:	/s/ David Lazar	 
	Name:	David Lazar	 
	Its:	Managing Member	 

 

    24

     

    

 

EXHIBIT

A

 

PROMISSORY

NOTE 

 

	$76,109	September

    30, 2021

 

MySpray

Therapeutics Inc. (“Maker”) promises to pay to the order of Nichol Martinuik, or his assigns, (“Holder”), the

principal sum of $76,109 with no interest thereon from this date, until fully paid All unpaid principal balance of this Note shall be

due and payable in full upon demand therefor by Holder.

 

In

the event an action is instituted to enforce or interpret any of the terms of this Note including but not limited to any action or participation

by Maker in, or in connection with, a case or proceeding under the Bankruptcy Code or any successor statute, each party shall bear all

their own expenses incurred at, before and after trial, appeal or review whether or not taxable as costs, including, without limitation,

attorney fees, witness fees (expert and otherwise), deposition costs, copying charges and other expenses.

 

All

parties to this Note hereby waive presentment, dishonor, notice of dishonor, and protest. All parties hereto consent to, and Holder is

hereby expressly authorized to make, without notice, any and all renewals, extensions, modifications or waivers of the time for or the

terms of payment of any sum or sums due hereunder, or under any documents or instruments relating to or securing this Note, or of the

performance of any covenants, conditions or agreements hereof or thereof or the taking or release of collateral securing this Note. Any

such action taken by Holder shall not discharge the liability of any party to this Note. This Note may not be modified or amended in

any respect except in a writing executed by the party to be charged.

 

This

Note has been executed and delivered in Saskatchewan, Canadian and shall be governed and construed in accordance with the laws of such.

Any action to enforce this Note or arising out of or related to this Note shall be heard in the Saskatchewan, Canadian courts to the

exclusion of all other venues and Maker hereby irrevocably consents to personal jurisdiction in Saskatchewan, Canadian in connection

with any such proceedings.

 

MAKER:

 

MYSPRAY

THERAPEUTICS, INC.,

a

Saskatchewan, Canadian company

 

	/s/

    Nichol Martinuik	 
	Nichol

    Martinuik, President	 

  

 

    A-1Exhibit

10.1

 

PROMISSORY

NOTE 

 

	$76,109	September 30, 2021

 

MySpray

Therapeutics Inc. (“Maker”) promises to pay to the order of Nichol Martinuik, or his assigns, (“Holder”), the

principal sum of $76,109 with no interest thereon from this date, until fully paid All unpaid principal balance of this Note shall be

due and payable in full upon demand therefor by Holder.

 

In

the event an action is instituted to enforce or interpret any of the terms of this Note including but not limited to any action or participation

by Maker in, or in connection with, a case or proceeding under the Bankruptcy Code or any successor statute, each party shall bear all

their own expenses incurred at, before and after trial, appeal or review whether or not taxable as costs, including, without limitation,

attorney fees, witness fees (expert and otherwise), deposition costs, copying charges and other expenses.

 

All

parties to this Note hereby waive presentment, dishonor, notice of dishonor, and protest. All parties hereto consent to, and Holder is

hereby expressly authorized to make, without notice, any and all renewals, extensions, modifications or waivers of the time for or the

terms of payment of any sum or sums due hereunder, or under any documents or instruments relating to or securing this Note, or of the

performance of any covenants, conditions or agreements hereof or thereof or the taking or release of collateral securing this Note. Any

such action taken by Holder shall not discharge the liability of any party to this Note. This Note may not be modified or amended in

any respect except in a writing executed by the party to be charged.

 

This

Note has been executed and delivered in Saskatchewan, Canadian and shall be governed and construed in accordance with the laws of such.

Any action to enforce this Note or arising out of or related to this Note shall be heard in the Saskatchewan, Canadian courts to the

exclusion of all other venues and Maker hereby irrevocably consents to personal jurisdiction in Saskatchewan, Canadian in connection

with any such proceedings.

 

MAKER:

 

MYSPRAY

THERAPEUTICS, INC.,

a

Saskatchewan, Canadian company

 

	/s/ Nichol

Martinuik	 
	Nichol

Martinuik, President

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00339-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00339-of-00352.parquet"}]]